# CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy

> **NCT02537977** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Tongji Hospital, Tongji University School of Medicine** · enrollment: 60 (estimated)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **BIOLOGICAL:** CD19-directed CAR-T cells

## Key facts

- **NCT ID:** NCT02537977
- **Lead sponsor:** Shanghai Tongji Hospital, Tongji University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-07
- **Primary completion:** 2020-06
- **Final completion:** 2020-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2018-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02537977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02537977, "CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02537977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*